JENNIFER J WHITEHAIR MD
Prescription History 1134236607
Obstetrics & Gynecology in Tuba City, AZ


Quality Rating: 70.58 out of 100 score

NPI Status: Active since August 23, 2006

Contact Information

167 NORTH MAIN STREET
TUBA CITY, AZ
ZIP 86045
Phone: (928) 283-2501
Fax: (928) 283-2677

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for JENNIFER J WHITEHAIR MD, an active Obstetrics & Gynecology specialist practicing in Tuba City, AZ. Our medical registry currently tracks 3 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 118 documented patient claims. Among these therapy options, the most frequently utilized medication is Myrbetriq, which accounts for 93 claims alone.

Medication Index

No matching medications currently found on file.

Cephalexin

Generic Formulation: CephalexinSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 282
AZ State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills33.9
Peer Average Days Supply370
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 64.5% less volume than the regional standard for practitioners inside AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $111.53 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.14

State Avg Cost Per Claim

$10.26

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria. This medication will not work for viral infections (such as common cold, flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Myrbetriq

Generic Formulation: MirabegronSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 93
30-Day Fills 93.0
Days Supply 2,468
AZ State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills68.3
Peer Average Days Supply2,003
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 138.5% higher than the standard regional baseline profile for AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $38,585.63 across this reporting matrix range.

Provider Avg Cost Per Claim

$414.90

State Avg Cost Per Claim

$763.81

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bladder problems (overactive bladder, neurogenic detrusor overactivity). Overactive bladder is a problem with how your bladder stores urine. Neurogenic detrusor overactivity is a bladder control condition caused by brain, spinal cord, or nerve problems. Symptoms of these conditions may include frequent urination, strong sudden urges to urinate that are hard to control, or involuntary loss of urine (incontinence). Mirabegron works by relaxing a certain bladder muscle (detrusor), which helps the bladder hold more urine and lessens symptoms of overactive bladder and neurogenic detrusor overactivity.

Premarin

Generic Formulation: Estrogens, ConjugatedSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 14
30-Day Fills 36.0
Days Supply 1,080
AZ State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills35.8
Peer Average Days Supply1,063
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,230.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$445.05

State Avg Cost Per Claim

$428.75

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation containing a mixture of water-soluble, conjugated estrogens derived wholly or in part from URINE of pregnant mares or synthetically from ESTRONE and EQUILIN. It contains a sodium-salt mixture of estrone sulfate (52-62%) and equilin sulfate (22-30%) with a total of the two between 80-88%. Other concomitant conjugates include 17-alpha-dihydroequilin, 17-alpha-estradiol, and 17-beta-dihydroequilin. The potency of the preparation is expressed in terms of an equivalent quantity of sodium estrone sulfate.

Therapeutic Applications

This medication is a female hormone. It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment. Certain estrogen products may also be used by men and women to treat cancers (certain types of prostate cancer, breast cancer that has spread to other parts of the body) and by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure).

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like JENNIFER J WHITEHAIR MD provides transparency into local medical care patterns within Tuba City, AZ.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Obstetrics & Gynecology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.